On the public citation graph
Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension
0 signed · 137 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/cpt.61openalex-snapshot
Racial/ethnic differences in drug disposition and response: Review of recently approved drugs
inferredcites →https://doi.org/10.1007/s13300-016-0211-xopenalex-snapshot
Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
inferredcites →https://doi.org/10.1016/j.jchf.2013.01.003openalex-snapshot
Heart Failure With Preserved Ejection Fraction in African Americans
inferredcites →https://doi.org/10.1016/s2213-8587(13)70084-6openalex-snapshot
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
inferredcites →https://doi.org/10.1016/s2213-8587(15)00417-9openalex-snapshot
Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
inferredcites →https://doi.org/10.1016/s2213-8587(16)30324-2openalex-snapshot
Minority underrepresentation in cardiovascular outcome trials for type 2 diabetes
inferredcites →https://doi.org/10.1056/nejm199304013281303openalex-snapshot
Single-Drug Therapy for Hypertension in Men -- A Comparison of Six Antihypertensive Agents with Placebo
inferredcites →https://doi.org/10.1056/nejmoa1504720openalex-snapshot
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
inferredcites →https://doi.org/10.1080/03007995.2017.1405800openalex-snapshot
Design of a 24-week trial of empagliflozin once daily in hypertensive black/African American patients with type 2 diabetes mellitus
inferredcites →https://doi.org/10.1093/ajh/7.1.7openalex-snapshot
Ethnic Differences in Circadian Hemodynamic Profile
inferredcites →https://doi.org/10.1093/ajh/hpw061openalex-snapshot
Arterial Stiffness: Going a Step Beyond
inferredcites →https://doi.org/10.1097/mbp.0b013e328344c713openalex-snapshot
The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy
inferredcites →https://doi.org/10.1111/dom.12572openalex-snapshot
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
inferredcites →https://doi.org/10.1111/dom.12962openalex-snapshot
Impact of empagliflozin on blood pressure in dipper and non‐dipper patients with type 2 diabetes mellitus and hypertension
inferredcites →https://doi.org/10.1111/j.1524-6175.2007.06395.xopenalex-snapshot
Comparison of Increasing Doses of Olmesartan Medoxomil, Losartan Potassium, and Valsartan in Patients With Essential Hypertension
inferredcites →https://doi.org/10.1111/jch.12747openalex-snapshot
Reductions in Mean 24‐Hour Ambulatory Blood Pressure After 6‐Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension
inferredcites →https://doi.org/10.1111/jch.12891openalex-snapshot
Influence of Age and Race on 24‐Hour Ambulatory Blood Pressure Responses to Valsartan, Hydrochlorothiazide, and Their Combination: Implications for Clinical Practice
inferredcites →https://doi.org/10.1161/cir.0000000000000534openalex-snapshot
Cardiovascular Health in African Americans: A Scientific Statement From the American Heart Association
inferredcites →https://doi.org/10.1161/cir.0000000000000558openalex-snapshot
Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association
inferredcites →https://doi.org/10.1161/cir.0000000000000597openalex-snapshot
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
inferredcites →https://doi.org/10.1161/circoutcomes.116.003166openalex-snapshot
Racial and Ethnic Differences in Antihypertensive Medication Use and Blood Pressure Control Among US Adults With Hypertension
inferredcites →https://doi.org/10.1161/circulationaha.116.021887openalex-snapshot
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
inferredcites →https://doi.org/10.1161/circulationaha.118.035083openalex-snapshot
Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus
inferredcites →https://doi.org/10.1161/jaha.115.002276openalex-snapshot
Reducing the Blood Pressure–Related Burden of Cardiovascular Disease: Impact of Achievable Improvements in Blood Pressure Prevention and Control
inferredcites →https://doi.org/10.1161/jaha.116.004007openalex-snapshot
Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients
inferredcites →https://doi.org/10.1161/jaha.117.005686openalex-snapshot
Effects of Sodium‐Glucose Cotransporter 2 Inhibitors on 24‐Hour Ambulatory Blood Pressure: A Systematic Review and Meta‐Analysis
inferredcites →https://doi.org/10.1177/1043659615575578openalex-snapshot
Barriers to Clinical Research Participation Among African Americans
inferredcites →https://doi.org/10.1177/1740774511427929openalex-snapshot
Factors influencing enrollment of African Americans in the Look AHEAD trial
inferredcites →https://doi.org/10.1186/1475-2840-13-28openalex-snapshot
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
inferredcites →https://doi.org/10.1186/s40360-017-0125-xopenalex-snapshot
Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes
inferredcites →https://doi.org/10.2337/dc14-1096openalex-snapshot
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
inferredcites →https://doi.org/10.2337/dc16-0041openalex-snapshot
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.3897/pharmacia.73.e184419zenodo-depositor-declared
Efficacy and safety of SGLT2 inhibitors in patients with type 2 diabetes mellitus: a systematic review
inferred← citeshttps://doi.org/10.1002/14651858.cd013650.pub2openalex-snapshot
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis
inferred← citeshttps://doi.org/10.1007/5584_2020_479openalex-snapshot
Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
inferred← citeshttps://doi.org/10.1007/978-3-030-86020-2_14openalex-snapshot
Cardiovascular Disease and Diabetic Kidney Disease
inferred← citeshttps://doi.org/10.1007/s10741-020-09954-8openalex-snapshot
Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
inferred← citeshttps://doi.org/10.1007/s11010-022-04552-8openalex-snapshot
Evaluation of selected antidiabetics in cardiovascular complications associated with cancer cachexia
inferred← citeshttps://doi.org/10.1007/s11886-019-1165-1openalex-snapshot
Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure
inferred← citeshttps://doi.org/10.1007/s11886-023-01966-8openalex-snapshot
New Potential Treatments for Resistant Hypertension
inferred← citeshttps://doi.org/10.1007/s11886-024-02115-5openalex-snapshot
Tackling the Disproportionate Burden of Resistant Hypertension in US Black Adults
inferred← citeshttps://doi.org/10.1007/s11906-022-01166-9openalex-snapshot
Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage
inferred← citeshttps://doi.org/10.1007/s11906-025-01342-7openalex-snapshot
Blood Pressure-Lowering Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists
inferred← citeshttps://doi.org/10.1007/s40618-024-02351-0openalex-snapshot
Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/b978-0-443-11985-9.00022-6openalex-snapshot
SGLT2 Inhibitors and Slowing Kidney Disease Progression From Diabetes
inferred← citeshttps://doi.org/10.1016/j.ahjo.2022.100159openalex-snapshot
SGLT2 inhibition for outcomes: Is this the panacea?
inferred← citeshttps://doi.org/10.1016/j.amjcard.2019.10.028openalex-snapshot
Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits
inferred← citeshttps://doi.org/10.1016/j.amjmed.2019.08.007openalex-snapshot
Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits
inferred← citeshttps://doi.org/10.1016/j.biopha.2023.115686openalex-snapshot
Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications
inferred← citeshttps://doi.org/10.1016/j.cger.2024.04.008openalex-snapshot
General Principles, Etiologies, Evaluation, and Management in Older Adults
inferred← citeshttps://doi.org/10.1016/j.diabet.2021.101224openalex-snapshot
SGLT2 inhibitors and the autonomic nervous system in diabetes: A promising challenge to better understand multiple target improvement
inferred← citeshttps://doi.org/10.1016/j.ecl.2021.05.006openalex-snapshot
Ethnic Disparities in Diabetes
inferred← citeshttps://doi.org/10.1016/j.ekir.2023.04.016openalex-snapshot
Managing Hyperkalemia in the Modern Era: A Case-Based Approach
inferred← citeshttps://doi.org/10.1016/j.eprac.2022.08.002openalex-snapshot
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
inferred← citeshttps://doi.org/10.1016/j.eprac.2024.03.001openalex-snapshot
Effect of Sodium-Glucose Cotransporter 2 Inhibitors on the 24-Hour Ambulatory Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension: An Updated Meta-Analysis
inferred← citeshttps://doi.org/10.1016/j.fct.2021.112406openalex-snapshot
Empagliflozin and neohesperidin protect against methotrexate-induced renal toxicity via suppression of oxidative stress and inflammation in male rats
inferred← citeshttps://doi.org/10.1016/j.ijcha.2021.100725openalex-snapshot
Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes
inferred← citeshttps://doi.org/10.1016/j.ijcrp.2025.200569openalex-snapshot
Dose-dependent effects of SGLT2 inhibitors on circadian blood pressure in hypertensive patients with diabetes: A systematic review and Bayesian network meta-analysis
inferred← citeshttps://doi.org/10.1016/j.jacadv.2025.102304openalex-snapshot
Effect of Empagliflozin on Whole Body, Cardiac, and Renal Sympathetic Outflows in Type 2 Diabetes
inferred← citeshttps://doi.org/10.1016/j.jchf.2021.08.006openalex-snapshot
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction
inferred← citeshttps://doi.org/10.1016/j.jchf.2022.09.002openalex-snapshot
Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
inferred← citeshttps://doi.org/10.1016/j.jnma.2020.05.018openalex-snapshot
Contemporary and Future Concepts on Hypertension in African Americans: COVID-19 and Beyond
inferred← citeshttps://doi.org/10.1016/j.jnma.2023.11.004openalex-snapshot
Managing hypertension in African Americans with heart failure: A guide for the primary care clinician
inferred← citeshttps://doi.org/10.1016/j.numecd.2020.05.030openalex-snapshot
Sodium-glucose co-transporter-2 inhibitors: peculiar “hybrid” diuretics that protect from target organ damage and cardiovascular events
inferred← citeshttps://doi.org/10.1016/j.pcad.2019.12.002openalex-snapshot
Update on hypertension in African-Americans
inferred← citeshttps://doi.org/10.1016/j.pcad.2019.12.008openalex-snapshot
The NEW-HOPE study and emerging therapies for difficult-to-control and resistant hypertension
inferred← citeshttps://doi.org/10.1016/j.pcad.2020.04.003openalex-snapshot
Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease
inferred← citeshttps://doi.org/10.1016/j.resp.2019.103316openalex-snapshot
Targeting oxidative stress, proinflammatory cytokines, apoptosis and toll like receptor 4 by empagliflozin to ameliorate bleomycin-induced lung fibrosis
inferred← citeshttps://doi.org/10.1016/j.tcm.2022.05.005openalex-snapshot
SGLT2 inhibitors in hypertension: Role beyond diabetes and heart failure
inferred← citeshttps://doi.org/10.1038/s41440-022-00867-7openalex-snapshot
Thermoreceptor TRPV1 regulates body weight and blood pressure in the absence of thermogenin
inferred← citeshttps://doi.org/10.1038/s41440-022-00874-8openalex-snapshot
Latest hypertension research to inform clinical practice in Asia
inferred← citeshttps://doi.org/10.1038/s41440-023-01301-2openalex-snapshot
Associations of SGLT2 genetic polymorphisms with salt sensitivity, blood pressure changes and hypertension incidence in Chinese adults
inferred← citeshttps://doi.org/10.1038/s41440-024-01723-6openalex-snapshot
The relationship between SGLT2 and systemic blood pressure regulation
inferred← citeshttps://doi.org/10.1038/s41574-020-0392-2openalex-snapshot
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1080/10408363.2021.1993439openalex-snapshot
Cardiovascular benefit of SGLT2 inhibitors
inferred← citeshttps://doi.org/10.1080/14656566.2020.1751815openalex-snapshot
An evaluation of empagliflozin and it’s applicability to hypertension as a therapeutic option
inferred← citeshttps://doi.org/10.1080/14779072.2021.1862548openalex-snapshot
Response to the letter to the editor entitled ‘Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic’
inferred← citeshttps://doi.org/10.1080/14779072.2022.2105204openalex-snapshot
New and developing pharmacotherapies for hypertension
inferred← citeshttps://doi.org/10.1080/14779072.2023.2159810openalex-snapshot
The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors
inferred← citeshttps://doi.org/10.1089/ars.2019.7923openalex-snapshot
Chronic Empagliflozin Treatment Reduces Myocardial Infarct Size in Nondiabetic Mice Through STAT-3-Mediated Protection on Microvascular Endothelial Cells and Reduction of Oxidative Stress
inferred← citeshttps://doi.org/10.1093/ajh/hpaa100openalex-snapshot
SGLT2 Inhibitors in Resistant Hypertension: A Sweet Solution
inferred← citeshttps://doi.org/10.1093/ajh/hpag111openalex-snapshot
Antihypertensive pharmacotherapy in chronic kidney disease: integrating estimated glomerular filtration rate-based cutoffs, mechanistic insights, and emerging therapeutic pathways
inferred← citeshttps://doi.org/10.1093/eurheartj/ehaf216openalex-snapshot
Obesity accelerates cardiovascular ageing
inferred← citeshttps://doi.org/10.1093/ndt/gfab048openalex-snapshot
Efficacy and safety of combination therapy with sodium–glucose cotransporter 2 inhibitors and renin–angiotensin system blockers in patients with type 2 diabetes: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1093/schbul/sbag050openalex-snapshot
Effects of Empagliflozin and Lifestyle Intervention on Improving Body Weight and Other Metabolic Parameters in Atypical Antipsychotics-treated Patients with Schizophrenia Spectrum Disorders—A Double-blind Randomized Placebo-controlled Trial
inferred← citeshttps://doi.org/10.1097/hco.0000000000000742openalex-snapshot
Hypertension and race/ethnicity
inferred← citeshttps://doi.org/10.1097/hco.0000000000000852openalex-snapshot
Management of hypertension in heart failure with preserved ejection fraction: is there a blood pressure goal?
inferred← citeshttps://doi.org/10.1097/hco.0000000000000865openalex-snapshot
Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i)
inferred← citeshttps://doi.org/10.1097/hco.0000000000001040openalex-snapshot
Eliminating hypertension disparities in U.S. non-Hispanic black adults: current and emerging interventions
inferred← citeshttps://doi.org/10.1097/hco.0000000000001145openalex-snapshot
Management of hypertension in heart transplant recipients: an ongoing conundrum
inferred← citeshttps://doi.org/10.1097/hjh.0000000000004386openalex-snapshot
Explaining blood pressure reduction heterogeneity in sodium-glucose cotransporter-2 inhibitor trials: a meta-analysis stratified by patient characteristics
inferred← citeshttps://doi.org/10.1111/dom.13805openalex-snapshot
Do GLP‐1RAs and SGLT‐2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1111/dom.14164openalex-snapshot
Cardiometabolic risk factor control in black and white people in the United States initiating sodium‐glucose co‐transporter‐2 inhibitors: A real‐world study
inferred← citeshttps://doi.org/10.1111/dom.14976openalex-snapshot
Effects of sodium‐glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients
inferred← citeshttps://doi.org/10.1111/dom.15499openalex-snapshot
Comparative analysis of hospitalization risk for incident heart failure in non‐Hispanic Black versus non‐Hispanic White individuals with type 2 diabetes on empagliflozin (Empa‐AA): Insights from real‐world data
inferred← citeshttps://doi.org/10.1111/imj.16189openalex-snapshot
Revisiting resistant hypertension: a comprehensive review
inferred← citeshttps://doi.org/10.1152/ajprenal.00119.2025openalex-snapshot
Gliflozins in hypertension: basic mechanisms and clinical insights
inferred← citeshttps://doi.org/10.1155/jdr/3733178openalex-snapshot
Gender Bias in Clinical Trials of Sodium–Glucose Cotransporter 2 Inhibitors for the Treatment of Type 2 Diabetes Mellitus: A Systematic Review
inferred← citeshttps://doi.org/10.1161/circulationaha.119.039044openalex-snapshot
Should Certain Antihyperglycemic Medications Be Preferred Over Antihypertensive Medications for Blood Pressure Control in Special Populations With Diabetes Mellitus?
inferred← citeshttps://doi.org/10.1161/circulationaha.121.053709openalex-snapshot
Are SGLT2 Inhibitors New Hypertension Drugs?
inferred← citeshttps://doi.org/10.1161/hypertensionaha.120.14791openalex-snapshot
Opportunities of Antidiabetic Drugs in Cardiovascular Medicine
inferred← citeshttps://doi.org/10.1161/hypertensionaha.121.17440openalex-snapshot
Nocturnal Hypertension and Heart Failure: Mechanisms, Evidence, and New Treatments
inferred← citeshttps://doi.org/10.1161/hypertensionaha.124.21361openalex-snapshot
Clinical Trials in Hypertension: A Mathematical Endorsement for Diagnosis and Treatment
inferred← citeshttps://doi.org/10.1161/jaha.119.015323openalex-snapshot
Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon‐Like Peptide‐1 Receptor Agonist and Sodium‐Glucose Cotransporter‐2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta‐Analysis
inferred← citeshttps://doi.org/10.1177/01410768231198442openalex-snapshot
Racial, ethnic and regional differences in the effect of sodium–glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials
inferred← citeshttps://doi.org/10.1177/10600280251317495openalex-snapshot
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Nervous System Disorders: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1177/20420188221142450openalex-snapshot
Effect of sodium-glucose cotransporter-2 inhibitors on patients with essential hypertension and pre-hypertension: a meta-analysis
inferred← citeshttps://doi.org/10.1186/s12902-022-01213-1openalex-snapshot
Safety and efficacy of Empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial
inferred← citeshttps://doi.org/10.1186/s12933-019-0852-yopenalex-snapshot
Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy
inferred← citeshttps://doi.org/10.1186/s12933-021-01410-7openalex-snapshot
Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure
inferred← citeshttps://doi.org/10.1253/circj.cj-24-0799openalex-snapshot
Investigation of the Effect of Empagliflozin on Cardiac Sympathetic and Parasympathetic Nerve Activity Analyzed From Heart Rate Variability Frequency in Japanese Patients With Type 2 Diabetes ― Results From the EMPYREAN Study ―
inferred← citeshttps://doi.org/10.14744/anatoljcardiol.2020.74154openalex-snapshot
Turkish Society of Cardiology Consensus Paper on Evaluation and Treatment of Resistant Hypertension
inferred← citeshttps://doi.org/10.15420/usc.2024.44openalex-snapshot
The Short and Sweet on Sodium–Glucose Cotransporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure
inferred← citeshttps://doi.org/10.20945/2359-3997000000319openalex-snapshot
Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia
inferred← citeshttps://doi.org/10.2174/1874467216666221017123333openalex-snapshot
Influence of SGLT2 Inhibitors in Remodeling, Substrate and Ion Metabolism of Myocardium to Prevent Cardiovascular Risks: Recent Work and Advancement
inferred← citeshttps://doi.org/10.2991/artres.k.191210.001openalex-snapshot
Decoupling of Heart Rate and Blood Pressure: Hemodynamic Counter-regulatory Mechanisms and their Implications
inferred← citeshttps://doi.org/10.31083/j.rcm2303106openalex-snapshot
Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease
inferred← citeshttps://doi.org/10.31083/j.rcm2312411openalex-snapshot
Addressing Cardiovascular Disparities in Racial/Ethnic Populations: The Blood Pressure-Lowering Effects of SGLT2 Inhibitors
inferred← citeshttps://doi.org/10.3389/fcvm.2022.1086672openalex-snapshot
Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure
inferred← citeshttps://doi.org/10.3389/fcvm.2025.1482918openalex-snapshot
Emerging horizons: clinical applications and multifaceted benefits of SGLT-2 inhibitors beyond diabetes
inferred← citeshttps://doi.org/10.3389/fendo.2023.1238399openalex-snapshot
Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.3389/fpubh.2021.668368openalex-snapshot
SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.3390/biomedicines13061413openalex-snapshot
Optimizing Nephron Performance: The Old, the New, and the New–Old Diuretic Therapies
inferred← citeshttps://doi.org/10.3390/ijms252212384openalex-snapshot
The Effects of SGLT2 Inhibitors on Blood Pressure and Other Cardiometabolic Risk Factors
inferred← citeshttps://doi.org/10.3390/jcm11051455openalex-snapshot
Rethinking Resistant Hypertension
inferred← citeshttps://doi.org/10.3390/jcm11164769openalex-snapshot
Efficacy and Safety of Empagliflozin in Type 2 Diabetes Mellitus Saudi Patients as Add-On to Antidiabetic Therapy: A Prospective, Open-Label, Observational Study
inferred← citeshttps://doi.org/10.3390/jcm12216868openalex-snapshot
Management of Hypertension in Diabetic Kidney Disease
inferred← citeshttps://doi.org/10.3390/nu17142281openalex-snapshot
Obesity and Cardiovascular Disease: Mechanistic Insights and Nutritional Management Strategies
inferred← citeshttps://doi.org/10.3390/pharmaceutics17050663openalex-snapshot
Engineering a Dual-Function Starch–Cellulose Composite for Colon-Targeted Probiotic Delivery and Synergistic Gut Microbiota Regulation in Type 2 Diabetes Therapeutics
inferred← citeshttps://doi.org/10.4093/dmj.2022.0421openalex-snapshot
Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis
inferred← citeshttps://doi.org/10.5049/ebp.2026.24.e6openalex-snapshot
Integrating Blood Pressure Control With Multi-Class Kidney Protective Agents in Diabetic Kidney Disease
inferred← citeshttps://doi.org/10.53853/encr.6.4.547openalex-snapshot
Neuropatía autonómica cardíaca diabética
inferred← citeshttps://doi.org/10.54133/ajms.v1i.29openalex-snapshot
Effects of SGLT2 Inhibitors on the Risks of Hypertension and Heart Failure in Diabetic Patients: A Systematic Review
inferred← citeshttps://doi.org/10.7759/cureus.77974openalex-snapshot
Hypertensive Diabetic Patients: Casual Pulse Pressure and Ambulatory Blood Pressure Monitoring (ABPM) as Superior Predictors of Future Cardiovascular Events
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.